Jacobio Pharmaceuticals Group First Half 2024 Earnings: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)

Jacobio Pharmaceuticals Group (HKG:1167) First Half 2024 Results

Key Financial Results

• Net loss: CN¥169.1m (loss widened by 1.7% from 1H 2023).
• CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jacobio Pharmaceuticals Group Earnings Insights

Looking ahead, revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Hong Kong are expected to grow by 28%.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 9.2% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Jacobio Pharmaceuticals Group that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.